Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.
Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.